Minelu Sonnenschein - Medigus VP of Operations
MDGS Stock | USD 2.84 0.16 5.97% |
VP
Dr. Minelu Menashe Sonnenschein was appointed Vice President Operations Israel at Medigus Ltd. effective June 1, 2014. Prior to this role, He served as Vice President Research Development at the Company from January 1, 2000 since 2014.
Age | 50 |
Tenure | 10 years |
Professional Marks | Ph.D |
Address | 10 Hanechoshet, Tel Aviv, Israel, 6971072 |
Phone | 972 73 370 4691 |
Web | https://www.medigus.com |
Medigus Management Efficiency
The company has return on total asset (ROA) of (0.0663) % which means that it has lost $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3072) %, meaning that it created substantial loss on money invested by shareholders. Medigus' management efficiency ratios could be used to measure how well Medigus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -0.22 in 2024. Return On Assets is likely to drop to -0.1 in 2024. At this time, Medigus' Asset Turnover is comparatively stable compared to the past year.Similar Executives
Found 1 records | VP Age | ||
Kari Stevens | Cigna Corp | N/A |
Management Performance
Return On Equity | -0.31 | ||||
Return On Asset | -0.0663 |
Medigus Ltd ADR Leadership Team
Elected by the shareholders, the Medigus' board of directors comprises two types of representatives: Medigus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medigus. The board's role is to monitor Medigus' management team and ensure that shareholders' interests are well served. Medigus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medigus' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ilan Oren, Executive Officer | ||
Efrat Venkert, External Director | ||
Anat Naschitz, Director | ||
Yaron Silberman, Chief Ltd | ||
Ori Hershkovitz, External Director | ||
Yair Rabinovitch, Director | ||
Menashe Sonnenschein, Vice President - Operations | ||
Gilad Mamlok, CFO | ||
Christopher Rowland, CEO and Director | ||
Eitan Machover, Independent Director | ||
Minelu Sonnenschein, VP of Operations | ||
Oded Yatzkan, Director of Fin. and Accounting and VP | ||
Nissim Darvish, Chairman of the Board | ||
Jeremy Starkweather, Director of Sales, Director of Marketing-United States | ||
Yuval Yanai, Director | ||
Aviel Shapira, Medical Director | ||
Yair Rabinowitch, Director | ||
Liron Carmel, Chief Officer | ||
Erez Haimovitz, Director | ||
Tali Dinar, Chief Officer | ||
Doron Birger, Director | ||
Tatyana Yossef, Controller | ||
Yaron Zilberman, Vice President - Sales and Marketing |
Medigus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medigus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.31 | ||||
Return On Asset | -0.0663 | ||||
Profit Margin | (0.13) % | ||||
Operating Margin | (0.09) % | ||||
Current Valuation | 2.05 M | ||||
Shares Outstanding | 1.89 M | ||||
Shares Owned By Institutions | 0.28 % | ||||
Number Of Shares Shorted | 5.05 K | ||||
Price To Earning | 33.86 X | ||||
Price To Book | 0.16 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medigus Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Medigus Ltd ADR information on this page should be used as a complementary analysis to other Medigus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Medigus Stock analysis
When running Medigus' price analysis, check to measure Medigus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigus is operating at the current time. Most of Medigus' value examination focuses on studying past and present price action to predict the probability of Medigus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigus' price. Additionally, you may evaluate how the addition of Medigus to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Transaction History View history of all your transactions and understand their impact on performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Medigus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medigus. If investors know Medigus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medigus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.70) | Revenue Per Share 67.313 | Quarterly Revenue Growth 0.527 | Return On Assets (0.07) | Return On Equity (0.31) |
The market value of Medigus Ltd ADR is measured differently than its book value, which is the value of Medigus that is recorded on the company's balance sheet. Investors also form their own opinion of Medigus' value that differs from its market value or its book value, called intrinsic value, which is Medigus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medigus' market value can be influenced by many factors that don't directly affect Medigus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medigus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Medigus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medigus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.